Published in Oncotarget on December 08, 2015
Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia (2016) 0.94
Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. Cancer Biol Med (2016) 0.76
Clonal Hematopoiesis of Indeterminate Potential. Dtsch Arztebl Int (2016) 0.75
Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. Oncotarget (2016) 0.75
Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia. Leukemia (2016) 0.75
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol (2016) 0.75
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress? J Clin Med (2017) 0.75
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature (2014) 6.83
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 3.75
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol (2011) 3.17
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol (2009) 2.26
The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program (2004) 2.23
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood (2011) 2.13
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood (2013) 2.12
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol (2011) 1.79
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood (2011) 1.44
Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol (2013) 1.44
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia (2012) 1.42
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia (2006) 1.13
Releasing the block: setting differentiation free with mutant IDH inhibitors. Cancer Cell (2013) 1.07
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood (2013) 1.05
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol (2013) 1.04
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget (2014) 0.81
Quantification of JAK2V617F mutation by next-generation sequencing technology. Am J Hematol (2013) 0.79
Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia (2011) 0.79